1. Home
  2. ALUR vs LEXX Comparison

ALUR vs LEXX Comparison

Compare ALUR & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALUR
  • LEXX
  • Stock Information
  • Founded
  • ALUR 2009
  • LEXX 2004
  • Country
  • ALUR United States
  • LEXX Canada
  • Employees
  • ALUR N/A
  • LEXX N/A
  • Industry
  • ALUR
  • LEXX Biotechnology: Pharmaceutical Preparations
  • Sector
  • ALUR
  • LEXX Health Care
  • Exchange
  • ALUR Nasdaq
  • LEXX Nasdaq
  • Market Cap
  • ALUR 22.8M
  • LEXX 20.9M
  • IPO Year
  • ALUR N/A
  • LEXX N/A
  • Fundamental
  • Price
  • ALUR $2.69
  • LEXX $0.99
  • Analyst Decision
  • ALUR Strong Buy
  • LEXX Strong Buy
  • Analyst Count
  • ALUR 3
  • LEXX 1
  • Target Price
  • ALUR $22.83
  • LEXX $7.00
  • AVG Volume (30 Days)
  • ALUR 857.0K
  • LEXX 73.8K
  • Earning Date
  • ALUR 05-14-2025
  • LEXX 07-11-2025
  • Dividend Yield
  • ALUR N/A
  • LEXX N/A
  • EPS Growth
  • ALUR N/A
  • LEXX N/A
  • EPS
  • ALUR N/A
  • LEXX N/A
  • Revenue
  • ALUR $28,304,000.00
  • LEXX $525,923.00
  • Revenue This Year
  • ALUR N/A
  • LEXX $0.62
  • Revenue Next Year
  • ALUR $49.35
  • LEXX $14.19
  • P/E Ratio
  • ALUR N/A
  • LEXX N/A
  • Revenue Growth
  • ALUR N/A
  • LEXX 29.95
  • 52 Week Low
  • ALUR $2.15
  • LEXX $0.92
  • 52 Week High
  • ALUR $88.75
  • LEXX $4.38
  • Technical
  • Relative Strength Index (RSI)
  • ALUR 49.19
  • LEXX 41.00
  • Support Level
  • ALUR $2.35
  • LEXX $0.92
  • Resistance Level
  • ALUR $3.00
  • LEXX $1.05
  • Average True Range (ATR)
  • ALUR 0.26
  • LEXX 0.06
  • MACD
  • ALUR -0.01
  • LEXX 0.01
  • Stochastic Oscillator
  • ALUR 37.36
  • LEXX 32.16

About ALUR Allurion Technologies Inc.

Allurion Technologies Inc is a medical device company that focuses on creating a weight loss platform to treat overweight patients. Its platform, the Allurion Program, features the world's first and only swallowable, procedure-less intragastric balloon for weight loss and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion VCS. Its proprietary intragastric balloon, the Allurion Balloon, is in the form of a swallowed capsule that is administered to patients under the guidance of a healthcare provider without surgery, endoscopy, or anesthesia.

About LEXX Lexaria Bioscience Corp.

Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH can increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood-brain barrier. The company has four reportable segments: Intellectual Property Licensing which generates maximum revenue, B2B Production, Research and Development, and Corporate. Geographically, it derives revenue from the United States and Canada.

Share on Social Networks: